What is the clinical evidence from this study?

Study design: Cohort. Population: Refractory cardiogenic shock (n=326). Intervention: ECPELLA (VA-ECMO and Impella) vs. VA-ECMO with or without IABP. Primary outcome: 30-day mortality (HR 0.48, 95% CI 0.35-0.66, p=<0.001).

What question did this study set out to answer?

This study aims to evaluate the effects of combining Impella with VA-ECMO on short-term mortality rates in patients with refractory cardiogenic shock.

February 6, 2026European Heart Journal

Impact of the combined use of VA-ECMO and impella (ECPELLA) on short-term mortality in cardiogenic shock patients receiving VA-ECMO: a propensity score-matched analysis

Q: What are the key findings of this study?

ECPELLA was associated with a significantly lower risk of 30-day mortality compared to VA-ECMO with or without IABP in patients with refractory cardiogenic shock (HR 0.48; 95% CI 0.35-0.66; p<0.001).

Q: What question did this study set out to answer?

This study aims to evaluate the effects of combining Impella with VA-ECMO on short-term mortality rates in patients with refractory cardiogenic shock.

View Full Paper

Ask AI

Bookmark

Key result

ECPELLA is linked to ~52% lower 30-day mortality vs. VA-ECMO in refractory cardiogenic shock.

HR 0.48
95% CI 0.35-0.66
P<0.001
n=326

Why the study?

Does ECPELLA reduce 30-day mortality in patients with refractory cardiogenic shock receiving VA-ECMO?

Population

326 patients with refractory cardiogenic shock, including those with cardiac arrest, who received VA-ECMO…

Comparison

Concomitant use of VA-ECMO and Impella (ECPELLA) vs VA-ECMO with or without intra-aortic balloon pump

Design

Cohort

Follow-up

30-day

Authors

TIT InamoriSaiseikai Kumamoto Hospital TUT UnokiSaiseikai Kumamoto Hospital TTTakamasa TanakaInterventional / Structural Cardiology

Discussion

Member takes

Implication

In patients with refractory cardiogenic shock, the combined use of VA-ECMO and Impella (ECPELLA) significantly improved 30-day survival compared to VA-ECMO alone or with IABP, despite an increased risk of complications.

Key Points

This study aims to evaluate the effects of combining Impella with VA-ECMO on short-term mortality rates in patients with refractory cardiogenic shock.
Retrospective review of 353 patients treated with VA-ECMO between January 2012 and December 2024.
Exclusion of 27 patients based on specific treatment requirements.
Division into ECPELLA group and VA-ECMO with or without IABP group, followed by propensity score matching.
Assessment of hemodynamic data, safety outcomes, and 30-day mortality.
116 patients from each group were analyzed after matching.
The ECPELLA group showed higher total MCS flow and lower catecholamine use within 72 hours.
The ECPELLA group had a higher incidence of complications such as bleeding and embolic stroke.
Kaplan-Meier analysis indicated significantly improved 30-day survival rates for the ECPELLA group (p < 0.001).
Multivariate analysis identified age, lactate level, and use of ECPELLA as independent predictors of mortality.

Study Design

Type

Cohort (n=326)

Multicenter

Structured PICO

Does ECPELLA reduce 30-day mortality in patients with refractory cardiogenic shock receiving VA-ECMO?

Population

326 patients with refractory cardiogenic shock requiring VA-ECMO, of whom 232 were propensity score-matched to compare ECPELLA versus VA-ECMO alone or with IABP for 30-day mortality.

Exposure

Concomitant use of VA-ECMO and Impella (ECPELLA)

Comparator

VA-ECMO with or without intra-aortic balloon pump (IABP) (62% received concomitant IABP support)

Outcome

30-day mortalityhard clinical

Main Result

Hazard Ratio: 0.48 (95% CI 0.35–0.66)

p-value: p=<0.001

Cite This Study

Inamori et al. (2025) conducted a cohort in Refractory cardiogenic shock (n=326). ECPELLA (VA-ECMO and Impella) vs. VA-ECMO with or without IABP was evaluated on 30-day mortality (HR 0.48, 95% CI 0.35-0.66, p=<0.001). ECPELLA was associated with a significantly lower risk of 30-day mortality compared to VA-ECMO with or without IABP in patients with refractory cardiogenic shock (HR 0.48; 95% CI 0.35-0.66; p<0.001).

synapsesocial.com/papers/698585ea8f7c464f23009c1e https://doi.org/10.1093/eurheartj/ehaf784.1566

View Full Paper

Ask AI

Bookmark

Impact of the combined use of VA-ECMO and impella (ECPELLA) on short-term mortality in cardiogenic shock patients receiving VA-ECMO: a propensity score-matched analysis

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Cite This Study

Impact of the combined use of VA-ECMO and impella (ECPELLA) on short-term mortality in cardiogenic shock patients receiving VA-ECMO: a propensity score-matched analysis

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Cite This Study

Also Consider

Also Consider